Dupilumab for Moderate-to-Severe Chronic Prurigo Nodularis: A Retrospective Real-World Study of Effectiveness, Safety, and Prolonged Dosing Intervals
Chronic prurigo nodularis (CPN) is a multidimensional neuro-immunocutaneous disease characterized by severe, persistent pruritus, and the development of nodular lesions caused by repeated scratching, often associated with sleep disruption, psychological distress, and impaired quality of life. Dupilumab has demonstrated efficacy and safety in clinical trials, but evidence regarding the use of prolonged dosing intervals, and potential modifiers of response in real-world settings remains limited. We conducted a single-center, retrospective, observational study of adults with moderate-to-severe CPN treated with dupilumab in routine clinical practice. The primary endpoint was clinically meaningful pruritus improvement at week 24, defined as a ≥ 4-point reduction in Worst Itch–Numeric Rating Scale (WI-NRS). Secondary outcomes included achievement of Investigator’s Global Assessment for Prurigo Nodularis-Stage (IGA PN-S) 0/1 and longitudinal changes in pruritus, nodular lesion burden, sleep disturbance, and quality of life. Adverse events, treatment discontinuation, exploratory baseline predictors of response, and patterns of dosing-interval extension and return to the standard every-2-week regimen were also recorded. In total, 26 patients were included. Median age at dupilumab initiation was 45.5 years (interquartile range [IQR] 33–53 years), and median follow-up was 50 weeks (IQR 32–62 years). Baseline disease burden was substantial, with severe itch, marked quality-of-life impairment, sleep disturbance, elevated impulsivity scores, and psychiatric comorbidity in 19 patients (73%). At week 24, 59% of patients achieved a ≥ 4-point WI-NRS reduction, while 45% achieved IGA PN-S 0/1 and combined WI-NRS–IGA PN-S response. A sustained improvement in itch, clinical severity, and quality of life was observed among evaluable patients through later follow-up. Prolongation of the dupilumab dosing interval was attempted in nine controlled responders and maintained without return to the standard regimen in five patients. Psychiatric comorbidity was associated with lower odds of WI-NRS response at week 24. Adverse events occurred in two patients (7.7%) and led to treatment withdrawal in one owing to gastrointestinal disorder. Dupilumab showed real-world effectiveness and a favorable safety profile in moderate-to-severe CPN. These findings support individualized, multidisciplinary management and further prospective investigation of response predictors and dosing-interval prolongation strategies. Graphical Abstract available for this article. Chronic prurigo nodularis (CPN) is a long-lasting skin disease that causes very intense itching and hard itchy bumps. Scratching can keep the disease going, and many people also have sleep problems, emotional distress, and a major effect on daily life. Dupilumab is an injectable treatment that blocks two immune signals involved in inflammation and itch. Clinical trials have shown that dupilumab can help people with this disease, but less is known about how patients treated in everyday clinical practice will respond. In this study, we reviewed the medical records of 26 adults with moderate-to-severe CPN treated with dupilumab. After 24 weeks, 59% of patients who could be assessed had a meaningful reduction in worst itch, and in 45% the skin disease was clear or almost clear according to the doctor’s assessment. Improvements in itch, skin signs, and quality of life generally continued during later follow-up. Overall, nine patients with good disease control were able to receive dupilumab less often; however, four needed to return to the standard every-2-week schedule. Side effects were uncommon and led to stopping treatment in one patient. Patients with mental health conditions seemed less likely to have a strong itch response, but this finding needs confirmation. These results support care that is tailored to each person, including mental health support when needed.
Authors
- Marta Bertolín‐Colilla (ORCID: https://orcid.org/0000-0002-2514-3230)
- Emilio Berná‐Rico (ORCID: https://orcid.org/0000-0003-0348-5421)
- Nasser Mohammad Porras (ORCID: https://orcid.org/0000-0003-0070-2304)
- María José Tribó-Boixareu
- Laura Parra‐Navarro (ORCID: https://orcid.org/0009-0004-7906-7570)
- Ramon Maria Pujol (ORCID: https://orcid.org/0000-0002-5622-6055)
- Irene García‐Díez (ORCID: https://orcid.org/0000-0003-0382-2758)
- Andrea Ciudad (ORCID: https://orcid.org/0009-0003-8848-829X)
- Fernando Gallardo (ORCID: https://orcid.org/0000-0002-8996-3828)
- Maria Rivera-Lopez (ORCID: https://orcid.org/0009-0003-5810-9690)
Institutions
- Universitat Pompeu Fabra (ES)
- Hospital Del Mar (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1007/s13555-026-01893-w
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00